As a corollary, the same general diagnostic approach using a suite of novel SMART kits could also be equally applied to target and detect clinically significant RET and ROS1 fusions that are associated with the disease progression of other types of lung cancers [47]. This evidence concerns the gene ROS1 and lung carcinoma.